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Intranasal Deferoxamine (IN DFO) as a Treatment For Neurodegenerative Disease
Rodent Trial DesignBackground
Abstract
Future Directions
Neurodegenerative diseases represent a 
huge burden of disease and disability with 
no cure. 
Intranasally administered deferoxamine 
(IN DFO), an iron chelator, has decreased 
memory loss and improved motor function 
in rodent models of Alzheimer’s and 
Parkinson’s disease respectively.
DFO’s mechanism of memory-
improvement may involve chelation of 
excess iron, activation of HIF-1α, and/or 
inhibition (phosphorylation) of GSK-3β.
DFO shows promise as a potential new 
therapy for multiple forms of 
neurodegenerative disease.
What is DFO?
Deferoxamine (DFO) is a metal chelator, binding iron and 
other metals, allowing their elimination from the body.
How could DFO Help in Neurodegeneration?
Iron accumulation and overload is well-characterized in 
Alzheimer’s and Parkinson’s Disease and may be involved in 
the symptoms.
DFO may alleviate iron overload (also: anti-inflammatory)
DFO has been tested in several rodent models of 
neurodegenerative disease:
P301L: accumulates hyperphosphorylated
Tau (AD)
APP/PS1: accumulates presenilin, amyloid
(AD)
ICV/STZ: inducible AD model
6-OHDA: inducible PD model
After intranasal administration, rodents were 
assessed using validated tools:
Morris water maze/Radial arm water maze 
for learning and memory
Tapered balance beam, Rearing tube for 
motor function
Rodents were later euthanized, and brain tissue 
samples taken for biochemical analyses.
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DFO: A Potential Solution
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In all AD models: DFO significantly improved learning and 
memory, with shorter escape latencies from water mazes
In PD: rodents given IN DFO demonstrated improved motor 
function
AD-(Fine et. al., 2015)                               PD-(Fine et. al, 2014)
Summary of Proposed Mechanisms
GSK-3β Inhibition;
Reversal of plaque 
and tangle 
formation?
Thus far, we have shown IN DFO to restore learning, memory, 
and motor function in rodent models of AD and PD.
More work needs to be done in clarifying the molecular 
mechanism of its action, as well as following the long-term 
course of its impact on brain function.
Once we have further established long-term safety and efficacy 
in rodent models, we can move forward to clinical trials.
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Burden of Neurodegenerative Disease
Gradual loss of neuronal function leading 
to progressive cognitive and neurologic 
dysfunction.
One of the leading causes of death and 
disability
Alzheimer’s Disease (AD):
2 mill death/year
Parkinson’s Disease (PD): 
>100,000 deaths/yr  
The Need for Treatment
Current treatments can slow progression 
and partially alleviate the symptoms of 
neurodegeneration, but we have no curative 
therapy.
Figure 1: Route of intranasal administration 
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